Holen Sie sich die Stockscreener-App
1.64
0.61%
-0.01
Handel nachbörslich:
1.64
Schlusskurs vom Vortag:
$1.65
Offen:
$1.67
24-Stunden-Volumen:
37,850
Relative Volume:
0.35
Marktkapitalisierung:
$5.96M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.28M
KGV:
-0.5449
EPS:
-3.01
Netto-Cashflow:
$-9.78M
1W Leistung:
-7.34%
1M Leistung:
-21.15%
6M Leistung:
-29.91%
1J Leistung:
-77.36%
1-Tages-Spanne:
$1.61
$1.685
1-Wochen-Bereich:
$1.46
$1.8499
52-Wochen-Spanne:
$1.46
$10.96
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Firmenname
Ensysce Biosciences Inc
Sektor
Branche
Telefon
(858) 263-4196
Adresse
7946 IVANHOE AVENUE, LA JOLLA
Vergleichen Sie ENSC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
1.64 | 5.92M | 0 | -11.28M | -9.78M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ensysce Biosciences Inc Aktie (ENSC) Neueste Nachrichten
How Ensysce Biosciences Inc. stock performs in interest rate cyclesQuarterly Profit Review & Real-Time Buy Signal Notifications - Newser
Why Ensysce Biosciences Inc. stock attracts high net worth investorsIPO Watch & Free Weekly Chart Analysis and Trade Guides - Newser
Ensysce (NASDAQ: ENSC) secures MPAR overdose tech patent protection to 2042 - Stock Titan
Is Ensysce Biosciences Inc. stock near bottom after declineEarnings Beat & Weekly High Conviction Trade Ideas - Newser
Will Ensysce Biosciences Inc. stock outperform international peersProfit Target & Verified Stock Trade Ideas - Newser
Earnings Beat: Why Ensysce Biosciences Inc. stock is seen as undervalued2025 Volatility Report & Fast Gaining Stock Reports - BỘ NỘI VỤ
Ensysce Biosciences Inc. (ENSC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Ensysce Biosciences, Inc.Common Stock (NQ: ENSC - Markets Financial Content
[PRE 14A] Ensysce Biosciences, Inc. Preliminary Proxy Statement - Stock Titan
Will Ensysce Biosciences Inc. stock benefit from AI adoption2025 Volatility Report & Community Shared Stock Ideas - newser.com
Ensysce Biosciences’ Innovative Approach to Safer Opioid Use: A Clinical Study Update - MSN
Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach - The Joplin Globe
Ensysce (NASDAQ: ENSC) Receives FDA Agreement on PF614 Commercial Manufacturing Approach - Stock Titan
Why Ensysce Biosciences Inc. stock is popular among millennialsJuly 2025 Outlook & Growth Oriented Trade Recommendations - newser.com
FY2025 Earnings Estimate for ENSC Issued By Zacks Small Cap - Defense World
Real time social sentiment graph for Ensysce Biosciences Inc.New Guidance & Free Technical Pattern Based Buy Signals - newser.com
Is Ensysce Biosciences Inc. stock trading near support levelsTrade Exit Summary & Proven Capital Preservation Tips - newser.com
What the charts say about Ensysce Biosciences Inc. todayTrade Signal Summary & Weekly High Return Stock Forecasts - newser.com
How currency fluctuations impact Ensysce Biosciences Inc. stockWeekly Investment Recap & Technical Analysis for Trade Confirmation - newser.com
Momentum divergence signals in Ensysce Biosciences Inc. chart2025 Technical Overview & Expert Verified Stock Movement Alerts - newser.com
What catalysts could drive Ensysce Biosciences Inc. stock higherJuly 2025 Closing Moves & Weekly Top Gainers Alerts - newser.com
Ensysce Biosciences Secures $4M Financing for PF614 - The Globe and Mail
Will Ensysce Biosciences Inc. stock remain a Wall Street favorite2025 Year in Review & Short-Term Trading Opportunity Alerts - newser.com
[8-K] Ensysce Biosciences, Inc. Reports Material Event | ENSC SEC FilingForm 8-K - Stock Titan
Ensysce Biosciences : Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs - marketscreener.com
Ensysce Biosciences (NASDAQ: ENSC) closes $4M round, unlocking $16M for PF614 Phase 3 - Stock Titan
Ensysce Biosciences, Inc. announced that it has received $2.487 million in funding - MarketScreener
How high can Ensysce Biosciences Inc. stock goProduct Launch & Fast Exit/Entry Strategy Plans - newser.com
Why retail investors pile into Ensysce Biosciences Inc. stockJuly 2025 Weekly Recap & Trade Opportunity Analysis - newser.com
Ensysce Biosciences Reports Increased R&D Expenses Amid Net Loss - TipRanks
Ensysce Biosciences reports Q3 net loss - MarketScreener
Ensysce Biosciences (NASDAQ: ENSC) begins Phase 3 PF614 trial; Q3 net loss $3.7M - Stock Titan
Finanzdaten der Ensysce Biosciences Inc-Aktie (ENSC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.44%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):